Q1 2026 BioArctic AB Earnings Call Transcript

May 20, 2026 / 07:30 AM GMT

Release Date Price: $33.02

Transcript

Key Points

Positve

BioArctic AB (BRCTF) reported strong financial results with more than EUR 500 million in sales through its partner ACI's fiscal year.
The company's brain transporter technology and projects are progressing well, with increased focus on business development.
BioArctic AB (BRCTF) has established Leqembi as a disease-modifying treatment for Alzheimer's disease, with sales expected to exceed USD 900 million in 2026.
The company has initiated successful partnerships with major pharmaceutical companies like Bristol Myers Squibb and Novartis.
BioArctic AB (BRCTF) maintains a strong financial position with over 2 billion Swedish crowns in cash, allowing for continued investment in projects and potential dividend payments.

Negative

The company faces challenges in gaining immediate access to markets in Europe, particularly in Sweden, due to conservative health economic modeling assumptions.
Operating expenses have increased significantly, with expectations of a 40% to 60% rise in costs for 2026 compared to 2025.
The Nordic private market for Leqembi is not substantial, limiting immediate sales potential in the region.
There is uncertainty regarding the timeline for the brain transporter platform's expansion into different modalities.
The delay in the FDA's approval of the subcutaneous autoinjector for Leqembi could impact the ramp-up of sales throughout the year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BIOAb.ST - BioArctic AB
Q1 2026 BioArctic AB Earnings Call
May 20, 2026 / 07:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to BioArctic Q1 Report 2026. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key five on their telephone keypad. Now I will hand the conference over to CEO Gunnella Oswald with colleagues. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning and welcome to BioArctic's presentation for the first quarter of 2026.

It has been a strong start of the year for Biotic, following a transformative year of 2025 with record

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.